Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...

A well-known injectable birth control method is under fire after multiple studies linked it to a specific kind of brain tumor, and now, lawsuits are piling up against the drugmaker. […] The post ...

A new study has linked a type of injectable birth control with meningioma. The manufacturer says the claims are “without ...

Wall Street ended higher on Friday, capping off a strong week that saw both the Nasdaq Composite and S&P 500 finish the week ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Pfizer is currently arguing to dismiss the lawsuit, citing the FDA's rejection of their proposed warning. We’ve filed FOIA requests to obtain Pfizer’s request and the FDA’s denial.

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

According to Pfizer Inc., only two Depo-Provera lawsuits had been filed in the Philadelphia Court of Common Pleas as of the company's May 29 petition submission. However, one of those actions had ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

Patients who received the Pfizer drug Braftovi alongside standard of care colorectal cancer therapies had a 51% lower risk of dying than patients treated with the standard of care chemotherapy.